Using human iPSCs as an in vitro model for regenerative medicine and disease modelling
22 February 2019
The conventional drug discovery pathway is a very inefficient process with the majority of candidate drugs not reaching the market due to safety and/or efficacy issues. But the use of iPSCs allows high throughput screening of therapies and disease-specific treatment using patient-specific models.